Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial.

Abstract

Current treatments of functional dyspepsia (FD) are unsatisfied. Tricyclic antidepressants alter visceral hypersensitivity and brain-gut interaction. We assessed the efficacy and safety of nortriptyline in patients with FD. Patients diagnosed with FD according to Rome III criteria who failed to respond to proton pump inhibitor and prokinetic treatment were randomly assigned to either once daily 10-mg nortriptyline or placebo. The primary endpoint was the rate of responders defined as >50% reduction in dyspepsia symptom score after 8weeks of treatment. The secondary endpoints were improvement in quality of life as assessed by 36-Item Short Form Health Survey score and safety. Sixty-one patients (nortriptyline 28 and placebo 33) were enrolled. Dyspepsia symptom score and duration of symptoms were balanced at entry between both groups. Eight and seven patients in nortriptyline and placebo groups were lost to follow up. Seven patients withdrew due to mild adverse events (nortriptyline 1 and placebo 6). Overall, 19 with nortriptyline and 20 with placebo completed the study. Patients receiving nortriptyline did not achieve higher response rate than those in placebo in both intention-to-treat (53.6% vs 57.6%, P=0.75) and per-protocol (76.5% vs 73.7%, P=1.00) analyses. Nortriptyline did not provide improvement in quality of life. The mean difference was 3.8 (P=0.36) and 0.88 (P=0.86) by intention-to-treat and 2.9 (P=0.57) and 3.5 (P=0.57) by per-protocol analyses in physical and mental component, respectively. All adverse events were minor and similar in both groups. Nortriptyline was not superior to placebo in management of patients with FD.